IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Zemel et al. Art Unit: 1616

Application No: 10/066,057 Examiner: Abigail L. Fisher

Confirmation No: 8306

Filed: January 31, 2002 Atty. Docket No: 31894-192403

Customer No:

For: MATERIALS AND METHODS FOR THE TREATMENT OR PREVENTION OF

OBESITY

26694
PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution during the prosecution of this application, and that the documents be made of record therein and appear on any patent to issue therefrom. Copies of documents $\underline{C1} - \underline{C3}$ are enclosed.

This Information Disclosure Statement is filed after the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114, but before an action that closes prosecution (37 CFR 1.97(c)).

Documents <u>A1</u> and <u>C1-C2</u> were cited in document <u>C3</u>, an Office Action mailed January 14, 2009, in U.S. Appl. No. 10/017,568.

Application No.: 10/066,057 Docket No.: 31894-192403

In accordance with 37 CFR 1.97(e)(1), Applicants state that no item of information contained in this Information Disclosure Statement was known to any individual designated in 37

CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S.

patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-

patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement

shall not be construed to mean that a search has been made or that no other material information as

defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information

Disclosure Statement shall not be construed to be an admission that any patent, publication or other

information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR

1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to

be filed or which should have been filed herewith (or with any paper hereafter filed in this

application by this firm) to our Deposit Account No. 22-0261, under Order No. 31894-192403.

Dated: April 13, 2009

Respectfully submitted,

Electronic signature: /Thomas F. Barry/

Thomas F. Barry

Registration No.: 57,586

VENABLE LLP

P.O. Box 34385

Washington, DC 20043-9998

(202) 344-4000

(202) 344-8300 (Fax)

Attorney/Agent For Applicant

2